A Phase 1 interventional study of ALN-PNP and Placebo in Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH) and Genetic Risk Factor, sponsored by Regeneron Pharmaceuticals. Completed at 5 sites in South Korea. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-07-31.
Sponsored by Regeneron Pharmaceuticals · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 61 studies in Non-alcoholic Fatty Liver Disease with a site in Korea, Republic of — 7 open to participants now, 11 under way, 7 of them phase 3. Non-alcoholic Fatty Liver Disease · Korea, Republic of.
Among the 61 studies in Non-alcoholic Fatty Liver Disease with a site in Korea, Republic of, this one is the 53rd largest by enrollment of the 53 interventional ones that give a count, is one of 7 that started in 2024, is one of 4 in phase 1, and was the 48th registered.
1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →7 of the 61 studies in Non-alcoholic Fatty Liver Disease with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Korea, Republic of, United States, Argentina and 31 more countries
Ages 18+
Akero Therapeutics, Inc · Sites in Korea, Republic of, United States, Argentina and 20 more countries
Ages 18–80
Chungnam National University Hospital · Sites in Korea, Republic of
Ages 19+ · Healthy volunteers
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19–55 · Men only · Healthy volunteers
Hoffmann-La Roche · Sites in Korea, Republic of, United States, Argentina and 22 more countries
Ages 18–75
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
61 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 22 · Phase 3 12 · Phase 4 7
First in 2007; this study’s year is marked. 7 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 9 is below the median of 60 across 1,176 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 145 across the 53 interventional studies, 351 across the 8 observational. Of the 45 that completed or were terminated, 14 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 61 have an industry lead sponsor. The 10 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Regeneron Pharmaceuticals has 9 studies filed under Non-alcoholic Fatty Liver Disease — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 61 studies in Non-alcoholic Fatty Liver Disease with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is researching an experimental drug called ALN-PNP. This study is focused on participants who are known to have nonalcoholic fatty liver disease (NAFLD), and a specific variant of the patatin-like phospholipase domain containing 3 (PNPLA3) gene.
The aim of this study is to see how safe, tolerable, and effective the study drug is.
This study is looking at several other research questions, including:
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion Criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who are homozygous for the PNPLA3 rs738409:G risk allele will be randomized 1:1:1:1
Drug: Placebo
Participants who are homozygous for the PNPLA3 rs738409:G risk allele will be randomized 1:1:1:1
Drug: ALN-PNP
Participants who are homozygous for the PNPLA3 rs738409:G risk allele will be randomized 1:1:1:1
Drug: ALN-PNP
Participants who are homozygous for the PNPLA3 rs738409:G risk allele will be randomized 1:1:1:1
Drug: ALN-PNP
Participants who are homozygous for the PNPLA3 rs738409:G risk allele will be randomized 1:1:1:1
Drug: Placebo
Participants who are homozygous for the PNPLA3 rs738409:G risk allele will be randomized 1:1:1:1
Drug: ALN-PNP
Participants who are homozygous for the PNPLA3 rs738409:G risk allele will be randomized 1:1:1:1
Drug: ALN-PNP
Participants who are homozygous for the PNPLA3 rs738409:G risk allele will be randomized 1:1:1:1
Drug: ALN-PNP
Sponsor may elect to enroll participants who are heterozygous for the PNPLA3 rs738409:G risk allele and may be randomized 1:1
Drug: Placebo
Sponsor may elect to enroll participants who are heterozygous for the PNPLA3 rs738409:G risk allele and may be randomized 1:1
Drug: ALN-PNP
Part A: Administered as single subcutaneous (SC) injection on day 1 Part B and Part C: Administered SC every 12 weeks (Q12W x2)
Part A: Administered as single SC injection on day 1 Part B and Part C: Administered SC every 12 weeks (Q12W x2)
Incidence of treatment-emergent adverse events (TEAEs)
Time frame: Up to 253 days
Severity of TEAEs
Time frame: Up to 253 days
Change in liver fat fraction by magnetic resonance imaging proton density fat fraction (MRI-PDFF) in participants with NAFLD
Time frame: Baseline up to 253 days
Change in low-density lipoprotein cholesterol (LDL-C) in participants with NAFLD
Time frame: Baseline up to 253 days
Change in high-density lipoprotein cholesterol (HDL-C) in participants with NAFLD
Time frame: Baseline up to 253 days
Change in triglycerides (TG) in participants with NAFLD
Time frame: Baseline up to 253 days
Change in lipoprotein a (Lp(a)) in participants with NAFLD
Time frame: Baseline up to 253 days
Change in apolipoprotein A1 (ApoA1) in participants with NAFLD
Time frame: Baseline up to 253 days
Change in apolipoprotein B (ApoB) in participants with NAFLD
Time frame: Baseline up to 253 days
Concentration of ALN-PNP and potential major metabolite(s) in plasma over time
Time frame: Up to 253 days
Incidence of anti-drug antibodies (ADAs) to ALN-PNP
Time frame: Up to 253 days
Titer of anti-drug antibodies (ADAs) to ALN-PNP
Time frame: Up to 253 days
Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy
Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Ran from May 2024 to primary completion in Jul 2025, 13 months.
Of 104 industry-sponsored phase 1 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 13 months is above that.
Counting every sponsor, half of 125 studies reached it within 10 months; a quarter within 5 and three quarters within 21.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Non-alcoholic Fatty Liver Disease →